AUS
NZ
UK
CA
USA
IND
Highlights
- Verrica Pharmaceuticals has confirmed a 1-for-10 reverse stock split, effective Thursday.
- The reverse split will proportionately adjust outstanding equity instruments and trading will begin on a split-adjusted basis on Friday.
- Fractional shares will not be issued; instead, cash will be paid for any fractional entitlements.
Stock Split Calendar: Verrica Pharmaceuticals Confirms Reverse Split Implementation
The biotechnology sector, represented by indexes such as the Nasdaq Biotechnology Index (NBI) and the NYSE Arca Biotechnology Index (BTK), has experienced notable activity with corporate restructuring events. Among these developments, stock split calendar activity includes the announcement by Verrica Pharmaceuticals Inc. (NASDAQ:VRCA), a specialty dermatology therapeutics firm, regarding its upcoming 1-for-10 reverse stock split. The move comes amid ongoing financial realignment within the sector.
Details of the Reverse Stock Split
The reverse stock split will become effective at 5:00 p.m. Eastern Time on Thursday. Every 10 shares of the company's issued and outstanding common stock will be automatically consolidated into one share. The par value of each share will remain unchanged. This action had previously been approved by shareholders during Verrica’s annual general meeting.
Following the implementation, necessary proportional adjustments will be made to the per-share exercise prices and number of shares available under all outstanding stock options and warrants. The company’s 2018 Equity Incentive Plan and the 2024 Inducement Plan will also see their reserved shares adjusted in accordance with the split ratio.
Impact on Shareholders and Equity Structure
No fractional shares will be issued as part of the reverse split. Shareholders eligible for fractional entitlements will instead receive equivalent cash payments. This measure will apply equally across all existing shareholders and will not modify individual ownership percentages, apart from negligible differences due to the rounding of fractional shares.
Verrica Pharmaceuticals’ common stock is scheduled to commence trading on a split-adjusted basis on the Nasdaq Global Market on Friday. The company's new CUSIP number has also been assigned as part of the administrative update related to the split.
Changes to Share Count and Valuation Status
Before the reverse split, Verrica had a substantial number of shares outstanding. After the adjustment, this total will be reduced proportionally, with the final figure subject to minor changes based on the resolution of fractional shares.
The company’s market valuation remains in focus, as Verrica has been navigating financial pressures tied to cash flow and profitability metrics. These challenges have shaped recent corporate decisions, including the amended credit terms with financial partners.
Operational and Commercial Highlights
Verrica Pharmaceuticals continues to report growth in its commercial product, YCANTH, which saw a rise in sales volumes in the recent quarter. The company has also received milestone-based payments from its collaboration with Japan-based Torii Pharmaceutical, tied to progress in clinical trials for a dermatological product targeting common warts.
Additional payments are anticipated upon regulatory approval of YCANTH for molluscum contagiosum in the Japanese market, projected within the current year. In earlier disclosures, Verrica confirmed improved revenue figures despite a reported net loss under GAAP standards. Amendments to its credit agreement included waivers for specific financial periods in 2025, allowing the company greater flexibility in managing liquidity and strategic plans.
